PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Retinopathy of prematurity

Drugs in development · updated 30 October 2026

Retinopathy of prematurity: drugs in development

As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 6 drugs for retinopathy of prematurity. 2 are experimental, that is not yet approved in the United States.

6Active trials
2Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
OHB-607II1NCT03253263
FLQ-101I1NCT07093255

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DexmedetomidineIgalmi®, Precedex®III1NCT06067958
Bevacizumabavastin, MVASIII1NCT04634578
FentanylFentanyl Citrate Buccal Tablet, Subsys®I–II1NCT07112430
PropranololHemangeol®, Innopran Xl®II1NCT03083431

Sorted by most advanced phase and number of active trials.

All 6 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012178 “Retinopathy of Prematurity”.

ItalianoFrançaisDeutsch